https://www.pharmaradar360.com/article/medicines-eligible-for-northern-ireland-mhra-authorised-route-ea4846a98bf6c2a7Pharma Surgeen2026-06-23T14:17:25.000ZMedicines eligible for Northern Ireland MHRA Authorised Routehttps://www.pharmaradar360.com/article/hoffmann-ii-carbon-connecting-rod-f7e8d926ffd8e318Pharma Surgeen2026-06-23T12:00:00.000ZHoffmann® II Carbon Connecting Rodhttps://www.pharmaradar360.com/article/withdrawn-cancer-accelerated-approvals-9d91fd407d4e65c0Pharma Surgeen2026-06-23T11:52:49.000ZWithdrawn | Cancer Accelerated Approvalshttps://www.pharmaradar360.com/article/polio-global-eradication-nac-and-environmental-surveillance-28a88d7a1d6b4d94Pharma Surgeen2026-06-23T10:11:44.000ZPolio: global eradication, NAC and environmental surveillancehttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-februar-3b2232fe8c91f5e1Pharma Surgeen2026-06-23T07:26:06.000ZRespiratory syncytial virus (RSV) maternal vaccination coverage in England: February 2026https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-older-adults-vaccination-coverage-in-england-may-e370cce99107b990Pharma Surgeen2026-06-23T07:03:34.000ZRespiratory syncytial virus (RSV) older adults vaccination coverage in England: May 2026https://www.pharmaradar360.com/article/evonik-sells-hanau-pharmaceutical-ingredients-production-assets-to-prochem-6209a971c5dc25cbPharma Surgeen2026-06-23T03:12:22.000ZEvonik Sells Hanau Pharmaceutical Ingredients Production Assets To ProChemhttps://www.pharmaradar360.com/article/biotech-chief-says-industry-in-better-place-after-fda-changes-bea29e624d847877Pharma Surgeen2026-06-23T02:14:00.000ZBiotech Chief Says Industry in ‘Better Place’ After FDA Changeshttps://www.pharmaradar360.com/article/innovent-pfizer-deal-makes-joint-development-commercialization-pillar-in-biotech-ddb634b0622e63edPharma Surgeen2026-06-23T01:22:00.000ZInnovent-Pfizer deal makes joint development, commercialization pillar in biotech global pushhttps://www.pharmaradar360.com/article/why-this-mid-cap-biotech-could-be-the-dark-horse-threat-to-eli-lilly-and-novo-no-66bc714f3c69417cPharma Surgeen2026-06-23T01:11:55.000ZWhy This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordiskhttps://www.pharmaradar360.com/article/why-this-mid-cap-biotech-could-be-the-dark-horse-threat-to-eli-lilly-and-novo-no-78d5a8bfa98274adPharma Surgeen2026-06-23T00:35:00.000ZWhy This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordiskhttps://www.pharmaradar360.com/article/bio-usa-2026-china-s-biotech-rise-puts-korea-on-notice-koreabio-vp-0e4b14abe840ac58Pharma Surgeen2026-06-23T00:26:47.000Z[BIO USA 2026] China’s biotech rise puts Korea on notice: KoreaBIO VPhttps://www.pharmaradar360.com/article/ah-008-achieves-dual-regulatory-milestones-with-u-s-fda-ind-clearance-and-taiwan-bc85d2c9a1e61e7fPharma Surgeen2026-06-23T00:01:48.000ZAH-008 Achieves Dual Regulatory Milestones with U.S. FDA IND Clearance and Taiwan CDE Index Case Designationhttps://www.pharmaradar360.com/article/first-disease-modifying-therapy-for-nhs-use-to-delay-the-onset-of-type-1-diabete-899409ec5ea7bf35Pharma Surgeen2026-06-23T00:00:00.000ZFirst disease-modifying therapy for NHS use to delay the onset of type 1 diabetes recommendedhttps://www.pharmaradar360.com/article/view-all-news-articles-c59e11b18e2ad94dPharma Surgeen2026-06-23T00:00:00.000ZView all news articleshttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-9bf74aaecfa046d3Pharma Surgeen2026-06-23T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/submission-for-omb-review-30-day-comment-request-chimpanzee-research-use-form-of-c663790b02dc2fcdPharma Surgeen2026-06-23T00:00:00.000ZSubmission for OMB Review; 30-Day Comment Request; Chimpanzee Research Use Form (Office of the Director)https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-4240f569b06d1a5ePharma Surgeen2026-06-23T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Certification of Identity, Form FDA 3975https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-pot-37adf65d0b839dbaPharma Surgeen2026-06-23T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Potential Tobacco Product Violations Reporting Formhttps://www.pharmaradar360.com/article/privacy-act-of-1974-system-of-records-930d85a36215e53ePharma Surgeen2026-06-23T00:00:00.000ZPrivacy Act of 1974; System of Recordshttps://www.pharmaradar360.com/article/drug-label-update-kopa-haiku-ringworm-treatment-cream-8fa44caec5530ce6Pharma Surgeen2026-06-23T00:00:00.000ZDrug label update: Kopa Haiku Ringworm Treatment Creamhttps://www.pharmaradar360.com/article/epstein-barr-virus-associated-lymphoma-during-thiopurine-and-anti-tumour-necrosi-45a7bcebe7dc10e8Pharma Surgeen2026-06-23T00:00:00.000ZEpstein–Barr Virus-associated Lymphoma during Thiopurine and Anti-tumour Necrosis Factor Therapy: A Case Reporthttps://www.pharmaradar360.com/article/bispecific-antibody-drug-conjugates-targeting-egfr-and-lgr5-exert-potent-antitum-0d961ee471b64876Pharma Surgeen2026-06-23T00:00:00.000ZBispecific antibody-drug conjugates targeting EGFR and LGR5 exert potent antitumor activity in colorectal cancer modelshttps://www.pharmaradar360.com/article/comparative-clinical-value-of-hemogram-derived-inflammatory-indices-for-microvas-a9d67aae5f7aeb9cPharma Surgeen2026-06-23T00:00:00.000ZComparative Clinical Value of Hemogram-Derived Inflammatory Indices for Microvascular Complications in Type 2 Diabetes — a Retrospective Cross-Sectional Studyhttps://www.pharmaradar360.com/article/sequential-coexistence-of-small-lymphocytic-lymphoma-as-a-second-primary-tumor-a-c8671067ca5b9113Pharma Surgeen2026-06-23T00:00:00.000ZSequential Coexistence of Small Lymphocytic Lymphoma as a Second Primary Tumor and BCR:: ABL1-Positive Chronic Myeloid Leukemia: A Case Reporthttps://www.pharmaradar360.com/article/quality-of-recovery-qor-15-scale-from-statistical-significance-to-clinical-relev-59d691b6945ad0e4Pharma Surgeen2026-06-23T00:00:00.000ZQuality of Recovery (QoR)-15 Scale: From Statistical Significance to Clinical Relevance and Beyondhttps://www.pharmaradar360.com/article/boron-neutron-capture-therapy-for-recurrent-pediatric-sialoblastoma-the-first-cl-f2b6238e758d6d17Pharma Surgeen2026-06-23T00:00:00.000ZBoron neutron capture therapy for recurrent pediatric sialoblastoma: the first clinical experience and dosimetric considerations for skeletal safety with 4-year follow-uphttps://www.pharmaradar360.com/article/clinical-efficacy-of-piper-betle-l-nanoemulgel-as-an-adjunct-to-scaling-and-root-2afdc3fb1b250b6aPharma Surgeen2026-06-23T00:00:00.000ZClinical Efficacy of Piper betle L. Nanoemulgel as an Adjunct to Scaling and Root Planing in Chronic Periodontitis: A Randomized, Double-Blind, Placebo-Controlled Trialhttps://www.pharmaradar360.com/article/protective-outcomes-of-high-affinity-monoclonal-antibodies-against-drug-resistan-394f5cb702a12969Pharma Surgeen2026-06-23T00:00:00.000ZProtective outcomes of high-affinity monoclonal antibodies against drug-resistant plague strainshttps://www.pharmaradar360.com/article/evidence-like-error-and-physician-responsibility-in-retrieval-augmented-clinical-d3a5ebe9557a56baPharma Surgeen2026-06-23T00:00:00.000ZEvidence-like error and physician responsibility in retrieval-augmented clinical artificial intelligencehttps://www.pharmaradar360.com/article/clinical-and-histopathological-profile-of-breast-cancer-based-on-her2-stratifica-3865eb61b3cd6f94Pharma Surgeen2026-06-23T00:00:00.000ZClinical and Histopathological Profile of Breast Cancer Based on HER2 Stratification ASCO/CAP 2018: Analysis of HER2-Positive, Negative, Low, and Ultralowhttps://www.pharmaradar360.com/article/garengeot-hernia-preperitoneal-approach-in-the-context-of-strangulation-case-rep-23e74bd2a9a1ad57Pharma Surgeen2026-06-23T00:00:00.000ZGarengeot hernia: preperitoneal approach in the context of strangulation, case reporthttps://www.pharmaradar360.com/article/clinical-and-radiographic-outcomes-of-the-calcaneo-stop-procedure-for-symptomati-c138f1e181ede4bcPharma Surgeen2026-06-23T00:00:00.000ZClinical and Radiographic Outcomes of the Calcaneo-stop Procedure for Symptomatic Flexible Flatfoot in Adolescents: A Retrospective Cohort Study of 160 Feethttps://www.pharmaradar360.com/article/construction-and-validation-of-a-model-integrating-radiomics-and-clinical-featur-4b2261fd0533e19aPharma Surgeen2026-06-23T00:00:00.000ZConstruction and Validation of a Model Integrating Radiomics and Clinical Features for Predicting Microsatellite Status in Colorectal Cancerhttps://www.pharmaradar360.com/article/does-the-use-of-liposomal-bupivacaine-in-hip-fracture-surgery-have-any-advantage-f6982e4c584955f5Pharma Surgeen2026-06-23T00:00:00.000ZDoes the Use of Liposomal Bupivacaine in Hip Fracture Surgery Have Any Advantage Over Conventional Analgesia for Postoperative Pain Control?https://www.pharmaradar360.com/article/clinical-laboratory-sciences-in-the-kingdom-of-saudi-arabia-history-education-an-164359e74bfae1c0Pharma Surgeen2026-06-23T00:00:00.000ZClinical Laboratory Sciences in the Kingdom of Saudi Arabia: History, Education, and Current Landscapehttps://www.pharmaradar360.com/article/visualization-exploration-and-application-effect-of-drug-configuration-process-b-f7e7b12f823b74ccPharma Surgeen2026-06-23T00:00:00.000ZVisualization Exploration and Application Effect of Drug Configuration Process Based on Daytime Chemotherapy Interaction Design Information Systemhttps://www.pharmaradar360.com/article/retraction-note-clinical-significance-of-airway-mucus-hypersecretion-in-chronic-72cf7f77ea51ea1cPharma Surgeen2026-06-23T00:00:00.000ZRetraction note: Clinical significance of airway mucus hypersecretion in chronic obstructive pulmonary diseasehttps://www.pharmaradar360.com/article/early-procalcitonin-kinetics-and-28-day-mortality-in-critical-illness-a-pragmati-02c9af63363a52b3Pharma Surgeen2026-06-23T00:00:00.000ZEarly procalcitonin kinetics and 28-day mortality in critical illness: a pragmatic Bayesian modelling approachhttps://www.pharmaradar360.com/article/national-comparability-and-inter-laboratory-performance-of-cortisol-immunoassays-737d636594b4166aPharma Surgeen2026-06-23T00:00:00.000ZNational comparability and inter-laboratory performance of cortisol immunoassays and LC-MS/MS methodshttps://www.pharmaradar360.com/article/enhancing-the-norepinephrine-transporter-expression-and-lt-sup-gt-211-lt-sup-gt-b4be4d97fb686b5cPharma Surgeen2026-06-23T00:00:00.000ZEnhancing the Norepinephrine Transporter Expression and [<sup>211</sup>At]MABG Uptake with Vorinostat Preloading in the Pheochromocytoma Modelhttps://www.pharmaradar360.com/article/lipopolysaccharide-induced-changes-in-facial-expression-and-orofacial-movement-i-26681344f2d0a333Pharma Surgeen2026-06-23T00:00:00.000ZLipopolysaccharide-Induced Changes in Facial Expression and Orofacial Movement in Micehttps://www.pharmaradar360.com/article/clinical-electrophysiological-and-neuropathological-features-of-peripheral-neuro-a5078c8d6d410f32Pharma Surgeen2026-06-23T00:00:00.000ZClinical, Electrophysiological, and Neuropathological Features of Peripheral Neuropathies in People With T-Cell Lymphoproliferative Disorderhttps://www.pharmaradar360.com/article/clinical-reasoning-a-32-year-old-woman-with-progressive-vision-loss-and-confusio-191667e5dc6f22e5Pharma Surgeen2026-06-23T00:00:00.000ZClinical Reasoning: A 32-Year-Old Woman With Progressive Vision Loss and Confusionhttps://www.pharmaradar360.com/article/accuracy-of-final-canine-retraction-with-and-without-a-palatal-power-arm-using-i-65ed507e492c0c86Pharma Surgeen2026-06-23T00:00:00.000ZAccuracy of final canine retraction with and without a palatal power arm using in-house clear aligners: a randomized clinical trialhttps://www.pharmaradar360.com/article/clinical-outcomes-and-parental-of-two-stainless-steel-crown-systems-in-pediatric-e4dc2189d250e2d7Pharma Surgeen2026-06-23T00:00:00.000ZClinical outcomes and parental of two stainless steel crown systems in pediatric patients: a retrospective observational cohort studyhttps://www.pharmaradar360.com/article/development-and-validation-of-an-interpretable-machine-learning-model-for-early-5932586e500edad2Pharma Surgeen2026-06-23T00:00:00.000ZDevelopment and validation of an interpretable machine learning model for early hospital-based differentiation of chikungunya and dengue fever using routine clinical datahttps://www.pharmaradar360.com/article/low-dose-intrathecal-morphine-versus-intrathecal-fentanyl-for-post-caesarean-ana-8257ba3ef8bb526fPharma Surgeen2026-06-23T00:00:00.000ZLow-dose intrathecal morphine versus intrathecal fentanyl for post-caesarean analgesia in a resource-constrained setting: a pragmatic randomised trialhttps://www.pharmaradar360.com/article/beyond-primary-patents-strategic-intellectual-property-frameworks-for-sustained-51b56eac911ff5b6Pharma Surgeen2026-06-23T00:00:00.000ZBeyond primary patents: Strategic intellectual property frameworks for sustained pharmaceutical market dominance in US & EUhttps://www.pharmaradar360.com/article/midterm-clinical-and-echocardiographic-outcomes-after-transcatheter-aortic-valve-e87fae0a1af7928fPharma Surgeen2026-06-23T00:00:00.000ZMidterm Clinical and Echocardiographic Outcomes After Transcatheter Aortic Valve Replacement in Patients With Severe Bicuspid Aortic Valve Stenosishttps://www.pharmaradar360.com/article/a-slow-regular-rhythm-after-tavr-a-clinical-reasoning-exercise-5b37a5ccbaab2da6Pharma Surgeen2026-06-23T00:00:00.000ZA Slow Regular Rhythm After TAVR: A Clinical Reasoning Exercisehttps://www.pharmaradar360.com/article/angiotensin-receptor-neprilysin-inhibitor-in-heart-failure-with-preserved-ejecti-eba015785baed931Pharma Surgeen2026-06-23T00:00:00.000ZAngiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trialhttps://www.pharmaradar360.com/article/laroprovstat-the-first-oral-small-molecule-pcsk9-inhibitor-for-the-treatment-of-5ab6a734084092d7Pharma Surgeen2026-06-23T00:00:00.000ZLaroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patientshttps://www.pharmaradar360.com/article/active-and-passive-knitting-rhythm-on-eeg-909cd8ff72f7e7bePharma Surgeen2026-06-23T00:00:00.000ZActive and Passive Knitting Rhythm on EEGhttps://www.pharmaradar360.com/article/anatomy-and-structural-connectivity-of-the-opercula-43c308627870f779Pharma Surgeen2026-06-23T00:00:00.000ZAnatomy and Structural Connectivity of the Operculahttps://www.pharmaradar360.com/article/navigating-hantavirus-risk-in-transplantation-implications-for-clinical-practice-9678c597609254d1Pharma Surgeen2026-06-23T00:00:00.000ZNavigating Hantavirus Risk in Transplantation: Implications for Clinical Practicehttps://www.pharmaradar360.com/article/effect-of-a-liquid-crystal-vein-locator-on-intravenous-catheterization-in-young-43e4ca188cb0700dPharma Surgeen2026-06-23T00:00:00.000ZEffect of a liquid crystal vein locator on intravenous catheterization in young children: a randomized trialhttps://www.pharmaradar360.com/article/auditory-involvement-in-inflammatory-bowel-disease-clinical-predictors-and-progn-7d25a828ef951125Pharma Surgeen2026-06-23T00:00:00.000ZAuditory Involvement in Inflammatory Bowel Disease: Clinical Predictors and Prognostic Implicationshttps://www.pharmaradar360.com/article/home-based-trimodal-prehabilitation-before-lung-resection-a-single-center-random-20766de38d39e2eePharma Surgeen2026-06-23T00:00:00.000ZHome-based trimodal prehabilitation before lung resection: a single-center randomized controlled trialhttps://www.pharmaradar360.com/article/a-commentary-on-clinical-outcomes-of-norepinephrine-phenylephrine-vs-norepinephr-c82a0742df1a61f7Pharma Surgeen2026-06-23T00:00:00.000ZA commentary on “Clinical outcomes of norepinephrine-phenylephrine vs. norepinephrine-vasopressin in septic shock: a retrospective cohort study”https://www.pharmaradar360.com/article/excerpts-from-march-april-2025-issue-of-acce-news-0e93327c8e86f993Pharma Surgeen2026-06-23T00:00:00.000ZExcerpts from March-April 2025 Issue of ACCE Newshttps://www.pharmaradar360.com/article/risk-management-7-safety-service-contract-management-ad357e6c88415d57Pharma Surgeen2026-06-23T00:00:00.000ZRisk Management 7 Safety Service Contract Managementhttps://www.pharmaradar360.com/article/doctronic-raises-40-billion-in-series-b-funding-4553886b441da389Pharma Surgeen2026-06-23T00:00:00.000ZDoctronic Raises $40 Billion in Series B Fundinghttps://www.pharmaradar360.com/article/osu-chs-tops-us-news-rankings-in-serving-health-care-shortage-areas-3d2a35bfa6f51abcPharma Surgeen2026-06-23T00:00:00.000ZOSU-CHS Tops US News Rankings in Serving Health Care Shortage Areashttps://www.pharmaradar360.com/article/circa-scientific-inc-appoints-medtech-executive-vafa-jamali-to-board-of-director-781a2e622a0e39caPharma Surgeen2026-06-23T00:00:00.000ZCIRCA Scientific, Inc. Appoints MedTech Executive Vafa Jamali to Board of Directorshttps://www.pharmaradar360.com/article/the-qsmr-shift-why-htm-is-the-new-frontline-of-hospital-risk-bef3bc8bb3c850aePharma Surgeen2026-06-23T00:00:00.000ZThe QSMR Shift: Why HTM Is the New Frontline of Hospital Riskhttps://www.pharmaradar360.com/article/reasons-for-different-laboratory-results-in-northern-sudan-case-study-in-merowe-3e9a6fa60b9006abPharma Surgeen2026-06-23T00:00:00.000ZReasons for Different Laboratory Results in Northern Sudan (Case Study in Merowe)https://www.pharmaradar360.com/article/transfer-learning-for-low-resource-genomic-mutation-detection-84b7c8196cb3e15bPharma Surgeen2026-06-23T00:00:00.000ZTransfer Learning for Low-resource Genomic Mutation Detectionhttps://www.pharmaradar360.com/article/response-to-panteghini-about-analytical-performance-specifications-for-immunosup-4e8f23e0fdb2702cPharma Surgeen2026-06-23T00:00:00.000ZResponse to Panteghini “About Analytical Performance Specifications for Immunosuppressive Drug Measurements”https://www.pharmaradar360.com/article/postsurgical-care-in-nail-surgery-recommendations-based-on-evidence-and-clinical-182f28ccfe2ce5f6Pharma Surgeen2026-06-23T00:00:00.000ZPostsurgical Care in Nail Surgery: Recommendations Based on Evidence and Clinical Experiencehttps://www.pharmaradar360.com/article/are-age-based-cutoffs-for-tha-logically-consistent-881f6dfe5985adb0Pharma Surgeen2026-06-23T00:00:00.000ZAre Age-based Cutoffs for THA Logically Consistent?https://www.pharmaradar360.com/article/corr-insights-are-lgbtq-allyship-symbols-associated-with-patient-trust-in-the-or-13e925a5551b5e3aPharma Surgeen2026-06-23T00:00:00.000ZCORR Insights®: Are LGBTQ+ Allyship Symbols Associated With Patient Trust in the Orthopaedic Surgeon? A Dual Cohort Surveyhttps://www.pharmaradar360.com/article/preoperative-distal-motor-latency-testing-and-long-term-outcomes-in-combined-lum-0bdb8751df8f878cPharma Surgeen2026-06-23T00:00:00.000ZPreoperative Distal Motor Latency Testing and Long-Term Outcomes in Combined Lumbar Spinal Stenosishttps://www.pharmaradar360.com/article/clinical-accuracy-and-applications-of-large-language-models-in-pediatric-orthope-64467496eb7263b3Pharma Surgeen2026-06-23T00:00:00.000ZClinical accuracy and applications of large language models in pediatric orthopedics: a systematic reviewhttps://www.pharmaradar360.com/article/comparative-10-year-performance-of-mammography-artificial-intelligence-polygenic-d1287b6b520cdd2cPharma Surgeen2026-06-23T00:00:00.000ZComparative 10-year performance of mammography artificial intelligence, polygenic, and clinical breast cancer risk models in the Kaiser Permanente Research Bankhttps://www.pharmaradar360.com/article/indications-protocols-and-interpretation-of-cardiovascular-imaging-for-the-evalu-54eef456929eb5f4Pharma Surgeen2026-06-23T00:00:00.000ZIndications, protocols, and interpretation of cardiovascular imaging for the evaluation and management of athletes: a clinical consensus statement of the European Association of Preventive Cardiology (EAPC) and the European Association of Cardiovascular Imaging (EACVI) of the European Society of Carhttps://www.pharmaradar360.com/article/heart-failure-inequality-and-the-decades-before-admission-2f3e36c67478b065Pharma Surgeen2026-06-23T00:00:00.000ZHeart failure, inequality, and the decades before admissionhttps://www.pharmaradar360.com/article/generating-evidence-using-electronic-alerts-during-routine-care-a-fully-automate-939392cabdd1837fPharma Surgeen2026-06-23T00:00:00.000ZGenerating evidence using electronic alerts during routine care: a fully automated randomised controlled trial of oral fluid restriction in acute heart failure (THIRST Alert Trial)https://www.pharmaradar360.com/article/indications-protocols-and-interpretation-of-cardiovascular-imaging-for-the-evalu-a0680ca0fe9ac766Pharma Surgeen2026-06-23T00:00:00.000ZIndications, protocols, and interpretation of cardiovascular imaging for the evaluation and management of athletes: a clinical consensus statement of the European Association of Preventive Cardiology (EAPC) and the European Association of Cardiovascular Imaging (EACVI) of the ESC: Part 1—Exercise imhttps://www.pharmaradar360.com/article/aptamer-based-biosensing-strategies-for-influenza-virus-detection-a-systematic-a-d2bdd03c4fecb470Pharma Surgeen2026-06-23T00:00:00.000ZAptamer-based biosensing strategies for influenza virus detection: a systematic and critical review of electrochemical and optical platformshttps://www.pharmaradar360.com/article/efficacy-and-safety-of-infigratinib-in-patients-with-refractory-advanced-gastric-33d7f14c42dc93a7Pharma Surgeen2026-06-23T00:00:00.000ZEfficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trialhttps://www.pharmaradar360.com/article/bridging-to-surgery-versus-palliation-in-malignant-colorectal-obstruction-compli-55fa6d82de65c728Pharma Surgeen2026-06-23T00:00:00.000ZBridging to surgery versus palliation in malignant colorectal obstruction: complication risks and mediation by clinical successhttps://www.pharmaradar360.com/article/european-society-of-clinical-pharmacy-bridging-gaps-clinical-pharmacy-in-the-dig-347c7274835be0c4Pharma Surgeen2026-06-23T00:00:00.000ZEuropean Society of Clinical Pharmacy: bridging gaps—clinical pharmacy in the digital transition of carehttps://www.pharmaradar360.com/article/from-relapse-to-survival-real-world-clinical-impact-of-a-multimodal-approach-in-959cfed93bd0cc14Pharma Surgeen2026-06-23T00:00:00.000ZFrom relapse to survival: real-world clinical impact of a multimodal approach in first-time recurrent glioblastomahttps://www.pharmaradar360.com/article/real-world-evidence-on-jak-inhibitors-in-rheumatology-practice-comparative-safet-a840c5bb1bf85506Pharma Surgeen2026-06-23T00:00:00.000ZReal-world evidence on JAK inhibitors in rheumatology practice: comparative safety, efficacy, and outcomes between JAK inhibitorshttps://www.pharmaradar360.com/article/promoting-the-utilization-of-rheumatologic-musculoskeletal-anatomy-a-50-year-tra-ff71c130251a5a02Pharma Surgeen2026-06-23T00:00:00.000ZPromoting the utilization of rheumatologic musculoskeletal anatomy: a 50-year travel loghttps://www.pharmaradar360.com/article/a-proof-of-concept-for-a-novel-mandibular-dental-implant-model-in-mice-b279740ffe67bcb1Pharma Surgeen2026-06-23T00:00:00.000ZA proof-of-concept for a novel mandibular dental implant model in micehttps://www.pharmaradar360.com/article/mechanisms-of-weight-gain-associated-with-valproic-acid-a-scoping-review-4427fd17a896fb69Pharma Surgeen2026-06-23T00:00:00.000ZMechanisms of weight gain associated with valproic acid: a scoping reviewhttps://www.pharmaradar360.com/article/a-living-biobank-of-sarcoma-patient-derived-cell-cultures-reveals-multi-omic-and-8a20af4409b4570fPharma Surgeen2026-06-23T00:00:00.000ZA living biobank of sarcoma patient‐derived cell cultures reveals multi‐omic and functional insights that capture disease heterogeneityhttps://www.pharmaradar360.com/article/diagnostic-value-and-treatment-responsiveness-of-ultrasound-features-in-correlat-96db68cb262131fcPharma Surgeen2026-06-23T00:00:00.000ZDiagnostic Value and Treatment Responsiveness of Ultrasound Features in correlation with clinical findings in Early Peripheral Spondyloarthritishttps://www.pharmaradar360.com/article/nct07663513-iparomlimab-and-tovorilimab-ql1706-combined-with-bevacizumab-and-che-91f9a619ff2542bfPharma Surgeen2026-06-23T00:00:00.000ZNCT07663513: Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancerhttps://www.pharmaradar360.com/article/nct07662720-a-phase-ii-trial-for-mor-antagonism-with-axelopran-to-enhance-immuno-6d9404801e96cad1Pharma Surgeen2026-06-23T00:00:00.000ZNCT07662720: A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancerhttps://www.pharmaradar360.com/article/nct07662369-cd45ra-depleted-dli-for-the-treatment-of-refractory-persistent-viral-7275833145f72f80Pharma Surgeen2026-06-23T00:00:00.000ZNCT07662369: CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantationhttps://www.pharmaradar360.com/article/nct07658729-effects-of-music-therapy-in-chronic-neck-pain-4d5c73290f5b7c00Pharma Surgeen2026-06-23T00:00:00.000ZNCT07658729: Effects of Music Therapy in Chronic Neck Painhttps://www.pharmaradar360.com/article/nct07602296-evaluating-how-red-light-therapy-applied-to-the-head-affects-symptom-12631b675ab0433aPharma Surgeen2026-06-23T00:00:00.000ZNCT07602296: Evaluating How Red-light Therapy Applied to the Head Affects Symptoms, Daily Life, and Brain Activity in People With Dementia With Lewy Bodieshttps://www.pharmaradar360.com/article/nct07599176-partial-stem-cell-transplant-for-sickle-cell-disease-from-matched-do-d6f5336760d056f1Pharma Surgeen2026-06-23T00:00:00.000ZNCT07599176: Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donorshttps://www.pharmaradar360.com/article/nct07539311-study-to-assess-the-efficacy-and-safety-of-rina-s-in-participants-wi-17280bfeb0b28b57Pharma Surgeen2026-06-23T00:00:00.000ZNCT07539311: Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancershttps://www.pharmaradar360.com/article/nct07519772-a-clinical-study-of-mk-1045-in-people-with-non-hodgkin-lymphoma-mk-1-a50ac56f09684b1dPharma Surgeen2026-06-23T00:00:00.000ZNCT07519772: A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)https://www.pharmaradar360.com/article/nct07376785-can-smartphones-listen-to-your-heart-a-performance-study-on-detectin-1b65f23e69ececdbPharma Surgeen2026-06-23T00:00:00.000ZNCT07376785: Can Smartphones Listen to Your Heart? A Performance Study on Detecting Inborn Heart Diseases in Your Heart Soundshttps://www.pharmaradar360.com/article/nct07357831-a-phase-iii-trial-to-evaluate-the-efficacy-and-safety-of-mc2-01-crea-4829f5d92fc7a1e3Pharma Surgeen2026-06-23T00:00:00.000ZNCT07357831: A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjectshttps://www.pharmaradar360.com/article/nct07290257-long-term-low-intervention-safety-and-clinical-outcomes-clinical-stu-ca31c8eb093d01a3Pharma Surgeen2026-06-23T00:00:00.000ZNCT07290257: Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)https://www.pharmaradar360.com/article/nct07287540-anti-inflammatory-nutrition-on-the-outcomes-of-non-surgical-periodon-c32ffb70a8cf6cf9Pharma Surgeen2026-06-23T00:00:00.000ZNCT07287540: Anti-inflammatory Nutrition on the Outcomes of Non-surgical Periodontal Therapyhttps://www.pharmaradar360.com/article/nct07195734-testing-the-addition-of-chemotherapy-or-chemo-immunotherapy-to-the-u-eaef4d5ec3a3e699Pharma Surgeen2026-06-23T00:00:00.000ZNCT07195734: Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancerhttps://www.pharmaradar360.com/article/nct07157774-assessing-the-impact-of-muvalaplin-on-major-cardiovascular-events-in-0365f0b120f4423cPharma Surgeen2026-06-23T00:00:00.000ZNCT07157774: Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)https://www.pharmaradar360.com/article/nct07125430-shock-wave-treatment-in-patients-with-knee-osteoarthritis-ff924be33b7facecPharma Surgeen2026-06-23T00:00:00.000ZNCT07125430: Shock Wave Treatment in Patients With Knee Osteoarthritishttps://www.pharmaradar360.com/article/nct07102524-intrathecal-gene-therapy-for-slc13a5-citrate-transporter-disorder-f0ccb7294634825dPharma Surgeen2026-06-23T00:00:00.000ZNCT07102524: Intrathecal Gene Therapy For SLC13A5 Citrate Transporter Disorderhttps://www.pharmaradar360.com/article/nct07018323-a-study-to-assess-the-efficacy-safety-and-tolerability-of-imvt-1402-f149bff035a715c2Pharma Surgeen2026-06-23T00:00:00.000ZNCT07018323: A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Diseasehttps://www.pharmaradar360.com/article/nct06968806-study-on-ketorolac-for-improving-outcomes-and-prognosis-in-patients-aa833c73db263891Pharma Surgeen2026-06-23T00:00:00.000ZNCT06968806: Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissectionhttps://www.pharmaradar360.com/article/nct06953960-a-study-to-assess-adverse-events-and-change-in-disease-activity-of-o-c2f79e6dd1bdf31aPharma Surgeen2026-06-23T00:00:00.000ZNCT06953960: A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)https://www.pharmaradar360.com/article/nct06940141-rademikibart-add-on-treatment-of-an-acute-asthma-exacerbation-seabre-851ef98496416e60Pharma Surgeen2026-06-23T00:00:00.000ZNCT06940141: Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)https://www.pharmaradar360.com/article/nct06910293-whole-brain-dynamics-in-the-natural-menstrual-cycle-vs-an-ovarian-st-050dd6510d64a71cPharma Surgeen2026-06-23T00:00:00.000ZNCT06910293: Whole-Brain Dynamics in the Natural Menstrual Cycle vs. an Ovarian Stimulated Cycle: Impact of Hormonal Fluctuations on Healthy Women Undergoing Ovarian Stimulationhttps://www.pharmaradar360.com/article/nct06744283-experience-and-management-of-cancer-screening-related-anxiety-in-fan-4217b728233e0099Pharma Surgeen2026-06-23T00:00:00.000ZNCT06744283: Experience and Management of Cancer Screening-Related Anxiety in Fanconi Anemiahttps://www.pharmaradar360.com/article/nct06596694-study-of-patritumab-deruxtecan-in-participants-with-gastrointestinal-73a4841de8c7ca86Pharma Surgeen2026-06-23T00:00:00.000ZNCT06596694: Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)https://www.pharmaradar360.com/article/nct06581432-beamion-pantumor-1-a-study-to-test-whether-zongertinib-helps-people-8be8ee03c6cb9724Pharma Surgeen2026-06-23T00:00:00.000ZNCT06581432: Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterationshttps://www.pharmaradar360.com/article/nct06435910-engineered-dendritic-cell-vaccines-for-multiple-myeloma-9a5d61431549227cPharma Surgeen2026-06-23T00:00:00.000ZNCT06435910: Engineered Dendritic Cell Vaccines for Multiple Myelomahttps://www.pharmaradar360.com/article/nct06180746-study-of-the-conditions-of-the-effects-of-health-mediation-on-unders-95a59f24e4d17f43Pharma Surgeen2026-06-23T00:00:00.000ZNCT06180746: Study of the Conditions of the Effects of Health Mediation on Underserved Populationhttps://www.pharmaradar360.com/article/nct06132113-dareontm-7-a-study-to-test-how-well-different-doses-of-bi-764532-in-5628c29cc964e8f7Pharma Surgeen2026-06-23T00:00:00.000ZNCT06132113: DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancershttps://www.pharmaradar360.com/article/nct05829655-measuring-acute-drug-demand-in-humans-94c453913eebf7d6Pharma Surgeen2026-06-23T00:00:00.000ZNCT05829655: Measuring Acute Drug Demand in Humanshttps://www.pharmaradar360.com/article/nct05684965-xtx301-in-patients-with-advanced-solid-tumors-b681bb9719fb093fPharma Surgeen2026-06-23T00:00:00.000ZNCT05684965: XTX301 in Patients With Advanced Solid Tumorshttps://www.pharmaradar360.com/article/nct05437341-psma-cd70-bi-specific-car-t-cell-therapy-bf494d568cc2b4b2Pharma Surgeen2026-06-23T00:00:00.000ZNCT05437341: PSMA/CD70 Bi-specific CAR-T Cell Therapyhttps://www.pharmaradar360.com/article/nct05368207-pembrolizumab-in-small-cell-carcinoma-of-ovary-hypercalcemic-type-pa-a516bc7cd0e17c25Pharma Surgeen2026-06-23T00:00:00.000ZNCT05368207: Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patienthttps://www.pharmaradar360.com/article/nct05189223-a-brief-values-intervention-to-support-veterans-in-early-buprenorphi-29ceef5a86709d20Pharma Surgeen2026-06-23T00:00:00.000ZNCT05189223: A Brief Values Intervention to Support Veterans in Early Buprenorphine Treatmenthttps://www.pharmaradar360.com/article/nct04609046-testing-the-addition-of-lenalidomide-and-nivolumab-to-the-usual-trea-7f50f948c51ec8edPharma Surgeen2026-06-23T00:00:00.000ZNCT04609046: Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphomahttps://www.pharmaradar360.com/article/nct04181827-a-study-comparing-jnj-68284528-a-car-t-therapy-directed-against-b-ce-76be6951b93e0400Pharma Surgeen2026-06-23T00:00:00.000ZNCT04181827: A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myelomahttps://www.pharmaradar360.com/article/nct04010877-multiple-car-t-cell-therapy-targeting-aml-fd18700a4dd99196Pharma Surgeen2026-06-23T00:00:00.000ZNCT04010877: Multiple CAR-T Cell Therapy Targeting AMLhttps://www.pharmaradar360.com/article/nct03586661-niraparib-and-copanlisib-in-treating-patients-with-recurrent-endomet-db077523faac9e7fPharma Surgeen2026-06-23T00:00:00.000ZNCT03586661: Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancerhttps://www.pharmaradar360.com/article/nct03194906-memantine-for-prevention-of-cognitive-late-effects-in-pediatric-pati-91323c669a2b7beePharma Surgeen2026-06-23T00:00:00.000ZNCT03194906: Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumorshttps://www.pharmaradar360.com/article/nct01371630-inotuzumab-ozogamicin-and-combination-chemotherapy-in-treating-patie-fd01d55795bf1cd5Pharma Surgeen2026-06-23T00:00:00.000ZNCT01371630: Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemiahttps://www.pharmaradar360.com/article/nct00520975-bevacizumab-in-treating-patients-with-metastatic-breast-cancer-that-d10e048ec29a2e6bPharma Surgeen2026-06-23T00:00:00.000ZNCT00520975: Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEUhttps://www.pharmaradar360.com/article/nct00231400-pompe-disease-registry-protocol-489eefcfe7a3f241Pharma Surgeen2026-06-23T00:00:00.000ZNCT00231400: Pompe Disease Registry Protocolhttps://www.pharmaradar360.com/article/how-teva-s-ecopipam-tourette-nda-and-austedo-data-will-impact-teva-pharmaceutica-7ef5373b8c703795Pharma Surgeen2026-06-22T23:41:56.000ZHow Teva’s Ecopipam Tourette NDA and AUSTEDO Data Will Impact Teva Pharmaceutical Industries (TEVA) Investorshttps://www.pharmaradar360.com/article/did-new-voxzogo-and-bmn-333-data-just-shift-biomarin-pharmaceutical-s-bmrn-inves-c70a1d02c6358ffaPharma Surgeen2026-06-22T23:41:56.000ZDid New VOXZOGO and BMN 333 Data Just Shift BioMarin Pharmaceutical's (BMRN) Investment Narrative?https://www.pharmaradar360.com/article/majority-of-americans-value-women-s-safety-over-ease-of-abortion-drug-access-5ae088def45bbd22Pharma Surgeen2026-06-22T23:17:02.000ZMajority of Americans Value Women’s Safety over Ease of Abortion Drug Accesshttps://www.pharmaradar360.com/article/health-brief-fda-signals-reset-in-drug-reviews-03da7d5f869b1c43Pharma Surgeen2026-06-22T23:07:33.000ZHealth Brief: FDA signals reset in drug reviewshttps://www.pharmaradar360.com/article/nuvectis-announces-strategic-portfolio-expansion-via-license-agreement-for-ex-ch-9b9cb853baff095cPharma Surgeen2026-06-22T22:18:52.000ZNuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compoundshttps://www.pharmaradar360.com/article/fda-launches-pilot-to-speed-drug-testing-as-china-surges-in-biotech-race-636d335d2f832c3bPharma Surgeen2026-06-22T21:54:08.000ZFDA launches pilot to speed drug testing as China surges in biotech racehttps://www.pharmaradar360.com/article/ups-adds-27-cold-transfer-facilities-for-pharmaceutical-shipping-75cdcad87c620595Pharma Surgeen2026-06-22T21:53:36.000ZUPS adds 27 cold transfer facilities for pharmaceutical shippinghttps://www.pharmaradar360.com/article/chart-master-is-it-time-to-buy-biotech-3a4b344cd466e810Pharma Surgeen2026-06-22T21:49:00.000ZChart Master: Is it time to buy biotech?https://www.pharmaradar360.com/article/serratiopeptidase-pharmaceutical-enzyme-market-growth-forecast-to-2035-bioproces-2e7031a9f6270265Pharma Surgeen2026-06-22T21:26:25.000ZSerratiopeptidase Pharmaceutical Enzyme Market Growth Forecast to 2035: Bioprocessing and Therapeutic Demand Accelerate - News and Statisticshttps://www.pharmaradar360.com/article/biotech-rivalry-between-us-china-intensifies-poll-752b3c9a69236682Pharma Surgeen2026-06-22T21:15:12.000ZBiotech rivalry between US, China intensifies: Pollhttps://www.pharmaradar360.com/article/biotech-firms-add-financial-leaders-in-2026-918d3e7fe4e6bf35Pharma Surgeen2026-06-22T21:06:56.000ZBiotech firms add financial leaders in 2026https://www.pharmaradar360.com/article/new-paper-beyond-the-biotech-race-right-sizing-u-s-china-competition-in-a-human-fc548a178583314cPharma Surgeen2026-06-22T21:03:27.000ZNew Paper | Beyond the Biotech Race — Right-Sizing U.S.-China Competition in a Human-Centered Industryhttps://www.pharmaradar360.com/article/reuters-health-news-summary-e5ed56d421d9dd52Pharma Surgeen2026-06-22T21:00:43.000ZReuters Health News Summaryhttps://www.pharmaradar360.com/article/pfizer-announces-topline-phase-3-results-for-sigvotatug-vedotin-in-previously-tr-10dd1d3888b63bf3Pharma Surgeen2026-06-22T20:30:00.000ZPfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/fda-launches-effort-to-accelerate-drug-trials-527b522c43a7aad5Pharma Surgeen2026-06-22T19:54:22.000ZFDA Launches Effort to Accelerate Drug Trialshttps://www.pharmaradar360.com/article/legend-biotech-s-car-t-cell-therapy-shows-early-promise-in-sclc-other-tumors-9aae32f8c1d343f9Pharma Surgeen2026-06-22T19:31:59.000ZLegend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumorshttps://www.pharmaradar360.com/article/china-closing-in-but-us-leads-in-biotech-quality-commercial-reach-survey-finds-747b6f7045515d21Pharma Surgeen2026-06-22T19:27:06.000ZChina closing in but US leads in biotech quality, commercial reach, survey findshttps://www.pharmaradar360.com/article/abbvie-acquires-apogee-therapeutics-for-10-9-billion-pharmexec-af5c735154dfd7f4Pharma Surgeen2026-06-22T19:17:43.000ZAbbVie Acquires Apogee Therapeutics for $10.9 Billion | PharmExechttps://www.pharmaradar360.com/article/krystal-biotech-krys-is-up-7-2-after-institutional-ownership-surges-to-sector-le-1bf926d02e57b7c5Pharma Surgeen2026-06-22T18:58:15.000ZKrystal Biotech (KRYS) Is Up 7.2% After Institutional Ownership Surges To Sector-Leading Levelshttps://www.pharmaradar360.com/article/insilico-lands-potential-2-5bn-ai-biotech-partnership-fc5a71951a40abb0Pharma Surgeen2026-06-22T18:40:57.000ZInsilico lands potential $2.5bn AI biotech partnershiphttps://www.pharmaradar360.com/article/biotech-spotlight-innovative-laboratory-systems-9f6b22dc93c202d4Pharma Surgeen2026-06-22T18:37:18.000ZBiotech Spotlight: Innovative Laboratory Systemshttps://www.pharmaradar360.com/article/u-s-to-speed-up-early-drug-research-to-better-compete-with-china-63470b3aa9e54e42Pharma Surgeen2026-06-22T18:28:00.000ZU.S. to Speed Up Early Drug Research to Better Compete With Chinahttps://www.pharmaradar360.com/article/innovent-s-trispecific-antibody-ibi3003-advances-into-phase-3-for-relapsed-or-re-1e34914fc5276d31Pharma Surgeen2026-06-22T18:10:02.000ZInnovent's Trispecific Antibody IBI3003 Advances Into Phase 3 for Relapsed or Refractory Multiple Myelomahttps://www.pharmaradar360.com/article/novartis-lays-off-60-workers-at-flatiron-biotech-after-1-4b-acquisition-4b18747c347d10fdPharma Surgeen2026-06-22T18:09:00.000ZNovartis lays off 60 workers at Flatiron biotech after $1.4B acquisitionhttps://www.pharmaradar360.com/article/bulletin-phase-3-clinical-trial-success-for-smart-watch-epilepsy-app-800c1e3b1d55cd98Pharma Surgeen2026-06-22T17:57:01.000ZBulletin: Phase 3 Clinical Trial Success for Smart Watch Epilepsy Apphttps://www.pharmaradar360.com/article/the-new-eu-pharmaceutical-legislation-key-points-for-deal-teams-376fc5d762c5b24ePharma Surgeen2026-06-22T17:56:07.000ZThe New EU Pharmaceutical Legislation: Key Points for Deal Teamshttps://www.pharmaradar360.com/article/recon-abbvie-forges-10-9-billion-deal-with-apogee-us-fda-changes-tack-on-regenxb-c7f48b2c884fc197Pharma Surgeen2026-06-22T17:56:00.000ZRecon: AbbVie forges $10.9 billion deal with Apogee; US FDA changes tack on Regenxbio's rare disease gene therapyhttps://www.pharmaradar360.com/article/fda-s-focus-returns-to-compounding-and-telehealth-another-wave-of-warning-letter-e728d704ba1a2761Pharma Surgeen2026-06-22T17:52:52.000ZFDA’s Focus Returns to Compounding and Telehealth: Another Wave of Warning Lettershttps://www.pharmaradar360.com/article/ustr-launches-section-301-investigation-into-germany-s-underpayment-for-pharmace-9a5b586a67c95829Pharma Surgeen2026-06-22T17:52:37.000ZUSTR Launches Section 301 Investigation into Germany’s Underpayment for Pharmaceutical Productshttps://www.pharmaradar360.com/article/this-biotech-could-become-a-sleeper-hit-305a65076770de50Pharma Surgeen2026-06-22T17:45:00.000ZThis Biotech Could Become a ‘Sleeper’ Hithttps://www.pharmaradar360.com/article/pharma-goes-on-a-spending-spree-snapping-up-biotechs-in-a-hurry-eaf6ed3a0241d3b9Pharma Surgeen2026-06-22T16:55:52.000ZPharma goes on a spending spree, snapping up biotechs in a hurryhttps://www.pharmaradar360.com/article/fda-issues-nationwide-recall-for-popular-cough-drops-here-s-the-full-list-186f3366c7869bdbPharma Surgeen2026-06-22T16:47:59.000ZFDA Issues Nationwide Recall for Popular Cough Drops - Here's the Full Listhttps://www.pharmaradar360.com/article/pharmaceutical-majors-cut-investments-in-germany-eb452cf08c9402cfPharma Surgeen2026-06-22T16:33:51.000ZPharmaceutical Majors Cut Investments in Germanyhttps://www.pharmaradar360.com/article/abbvie-paying-10-9b-to-buy-waltham-biotech-c75ff3193fc59ba5Pharma Surgeen2026-06-22T16:31:26.000ZAbbVie paying $10.9B to buy Waltham biotechhttps://www.pharmaradar360.com/article/sanofi-s-r-d-head-exits-with-ai-biotech-xaira-s-exec-stepping-in-2a086694c6c84724Pharma Surgeen2026-06-22T16:28:25.000ZSanofi’s R&D head exits, with AI biotech Xaira’s exec stepping inhttps://www.pharmaradar360.com/article/to-prevent-the-burn-the-fda-finally-approves-a-new-sunscreen-daae3714c8b1c722Pharma Surgeen2026-06-22T16:20:00.000ZTo Prevent the Burn: The FDA Finally Approves a New Sunscreenhttps://www.pharmaradar360.com/article/oppenheimer-raises-definium-therapeutics-stock-price-target-on-trial-data-866b72e2f0c3737fPharma Surgeen2026-06-22T16:20:00.000ZOppenheimer raises Definium Therapeutics stock price target on trial datahttps://www.pharmaradar360.com/article/test-post-3d12995c1a7d7bf2Pharma Surgeen2026-06-22T16:11:40.000ZTest posthttps://www.pharmaradar360.com/article/fda-recall-is-your-blood-pressure-medication-affected-18e8c9aaf6d08ca4Pharma Surgeen2026-06-22T15:52:40.000ZFDA Recall: Is your blood pressure medication affected?https://www.pharmaradar360.com/article/uniqure-s-experimental-drug-shows-early-promise-in-difficult-to-treat-epilepsy-f1e1c6a86738bddePharma Surgeen2026-06-22T15:51:29.000ZuniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsyhttps://www.pharmaradar360.com/article/fda-to-launch-pilot-program-to-speed-up-early-stage-clinical-trials-e125885c8044f375Pharma Surgeen2026-06-22T15:49:32.000ZFDA to launch pilot program to speed up early-stage clinical trialshttps://www.pharmaradar360.com/article/an-international-conversation-on-child-health-equity-reflections-from-inrich-202-b1edb403488613f5Pharma Surgeen2026-06-22T15:48:14.000ZAn international conversation on child health equity: Reflections from INRICH 2026https://www.pharmaradar360.com/article/fda-issues-complete-response-letter-for-cytisinicline-nda-citing-manufacturing-d-1cd42e216802baf2Pharma Surgeen2026-06-22T15:48:12.000ZFDA Issues Complete Response Letter for Cytisinicline NDA, Citing Manufacturing Deficiencieshttps://www.pharmaradar360.com/article/fda-issues-crl-for-cytisinicline-for-smoking-cessation-in-adults-d327221192ddfeecPharma Surgeen2026-06-22T15:48:03.000ZFDA Issues CRL for Cytisinicline for Smoking Cessation in Adultshttps://www.pharmaradar360.com/article/us-fda-declines-to-approve-achieve-life-sciences-smoking-cessation-drug-9975e843938b52dfPharma Surgeen2026-06-22T15:45:55.000ZUS FDA declines to approve Achieve Life Sciences' smoking-cessation drughttps://www.pharmaradar360.com/article/enjoy-the-hot-weather-but-stay-safe-nhsggc-advice-for-mini-heatwave-95b7abe003760c56Pharma Surgeen2026-06-22T15:45:00.000ZEnjoy the hot weather but stay safe: NHSGGC advice for mini-heatwavehttps://www.pharmaradar360.com/article/fda-declines-to-approve-achieve-life-sciences-smoking-cessation-drug-q4-resubmis-28146f7b0c3f71b8Pharma Surgeen2026-06-22T15:44:44.000ZFDA Declines To Approve Achieve Life Sciences' Smoking Cessation Drug; Q4 Resubmission Plannedhttps://www.pharmaradar360.com/article/beyond-the-biotech-race-right-sizing-u-s-china-competition-in-a-human-centered-i-ae5d228824c3ea84Pharma Surgeen2026-06-22T15:43:21.000ZBeyond the Biotech Race — Right-Sizing U.S.-China Competition in a Human-Centered Industryhttps://www.pharmaradar360.com/article/2026-un-high-level-meeting-on-hiv-aids-2d236c15b6583a34Pharma Surgeen2026-06-22T15:43:16.000Z2026 UN High-Level Meeting on HIV/AIDShttps://www.pharmaradar360.com/article/engineers-test-validate-novel-method-to-improve-pharmaceutical-research-and-deve-54be41fd93792507Pharma Surgeen2026-06-22T15:40:07.000ZEngineers test, validate novel method to improve pharmaceutical research and developmenthttps://www.pharmaradar360.com/article/dhsc-spending-over-500-9d0eec9bf491adbdPharma Surgeen2026-06-22T15:31:28.000ZDHSC spending over £500https://www.pharmaradar360.com/article/dhsc-spending-over-500-may-2026-db6ae840e2e515bePharma Surgeen2026-06-22T15:31:20.000ZDHSC: spending over £500, May 2026https://www.pharmaradar360.com/article/machine-learning-based-drug-renal-clearance-predictor-development-and-applicatio-88cc40c758f9c7ffPharma Surgeen2026-06-22T15:20:42.000ZMachine Learning based drug renal clearance predictor development and applicationhttps://www.pharmaradar360.com/article/chemaxon-retires-jchem-for-office-lite-da9f717867504070Pharma Surgeen2026-06-22T15:17:17.000ZChemaxon retires JChem for Office Litehttps://www.pharmaradar360.com/article/why-do-some-children-get-sicker-from-the-flu-than-other-kids-and-how-do-vaccines-74cb40238c44138aPharma Surgeen2026-06-22T15:17:14.000ZWhy Do Some Children Get Sicker From the Flu Than Other Kids and How Do Vaccines Play a Role?https://www.pharmaradar360.com/article/fda-backs-entera-bio-s-750-patient-osteoporosis-trial-for-eb613-693ffa8a17a67179Pharma Surgeen2026-06-22T15:17:07.000ZFDA backs Entera Bio’s 750-patient osteoporosis trial for EB613https://www.pharmaradar360.com/article/leaf4life-engages-phase-advance-to-predict-clinical-outcomes-for-16-phase-3-tria-6188300926a7527dPharma Surgeen2026-06-22T15:11:10.000ZLeaf4Life Engages Phase Advance To Predict Clinical Outcomes for 16 Phase 3 Trialshttps://www.pharmaradar360.com/article/ukhsa-privacy-notice-0e7ed345cb406e76Pharma Surgeen2026-06-22T15:06:08.000ZUKHSA privacy noticehttps://www.pharmaradar360.com/article/fda-announces-recall-of-common-blood-pressure-medication-d21c3f4d8d1d7881Pharma Surgeen2026-06-22T15:04:55.000ZFDA Announces Recall of Common Blood Pressure Medicationhttps://www.pharmaradar360.com/article/fda-launches-new-pilot-to-speed-early-stage-drug-development-58b1b86f7c00b1dcPharma Surgeen2026-06-22T15:03:00.000ZFDA Launches New Pilot to Speed Early-Stage Drug Developmenthttps://www.pharmaradar360.com/article/lilly-declares-third-quarter-2026-dividend-78b7482ce78a846fPharma Surgeen2026-06-22T15:00:00.000ZLilly declares third-quarter 2026 dividendhttps://www.pharmaradar360.com/article/merck-reports-positive-phase-3-tulisokibart-results-8fb7e700065dd027Pharma Surgeen2026-06-22T14:53:00.000ZMerck reports positive Phase 3 tulisokibart resultshttps://www.pharmaradar360.com/article/abbvie-deepens-immunology-legacy-in-10-9bn-apogee-buyout-8cbee8b8a01dbb67Pharma Surgeen2026-06-22T14:41:45.000ZAbbVie deepens immunology legacy in $10.9bn Apogee buyouthttps://www.pharmaradar360.com/article/letter-to-baroness-casey-progress-on-adult-social-care-reform-recommendations-e4ba38a0b5ae62cePharma Surgeen2026-06-22T14:39:00.000ZLetter to Baroness Casey: progress on adult social care reform recommendationshttps://www.pharmaradar360.com/article/achieve-life-sciences-receives-fda-rejection-on-manufacturing-issues-7212668f1188a4c4Pharma Surgeen2026-06-22T14:38:31.000ZAchieve Life Sciences receives FDA rejection on manufacturing issueshttps://www.pharmaradar360.com/article/here-s-why-you-should-add-lxrx-stock-to-your-portfolio-now-3348713da485170ePharma Surgeen2026-06-22T14:36:00.000ZHere's Why You Should Add LXRX Stock to Your Portfolio Nowhttps://www.pharmaradar360.com/article/merck-s-ibd-drug-from-10-8b-prometheus-deal-claims-its-first-phase-3-win-00c81de7f718bba8Pharma Surgeen2026-06-22T14:32:00.000ZMerck’s IBD drug from $10.8B Prometheus deal claims its first Phase 3 winhttps://www.pharmaradar360.com/article/menb-vaccination-eligible-residential-further-education-settings-ea1c926b97083608Pharma Surgeen2026-06-22T14:31:58.000ZMenB vaccination: eligible residential further education settingshttps://www.pharmaradar360.com/article/fda-cites-manufacturing-issues-for-cytisinicline-ab59094988eb2fdcPharma Surgeen2026-06-22T14:25:20.000ZFDA Cites Manufacturing Issues for Cytisiniclinehttps://www.pharmaradar360.com/article/women-s-college-hospital-launches-trauma-therapy-network-of-ontario-16caf432205dd826Pharma Surgeen2026-06-22T14:24:54.000ZWomen’s College Hospital launches Trauma Therapy Network of Ontariohttps://www.pharmaradar360.com/article/us-to-investigate-germany-s-proposed-drug-spending-reforms-deea9e2183f697f7Pharma Surgeen2026-06-22T14:14:27.000ZUS to investigate Germany's proposed drug spending reformshttps://www.pharmaradar360.com/article/vaccine-update-issue-371-may-2026-nin-special-35bf814080bca537Pharma Surgeen2026-06-22T14:10:15.000ZVaccine update: issue 371, May 2026, NIN specialhttps://www.pharmaradar360.com/article/purdue-engineers-test-validate-novel-method-to-improve-pharmaceutical-r-d-95070b87f634b700Pharma Surgeen2026-06-22T14:09:38.000ZPurdue engineers test, validate novel method to improve pharmaceutical R&Dhttps://www.pharmaradar360.com/article/america-is-losing-ground-to-china-in-clinical-research-and-medical-innovation-c5b5431505a9a74cPharma Surgeen2026-06-22T14:05:16.000ZAmerica is losing ground to China in clinical research and medical innovationhttps://www.pharmaradar360.com/article/offworld-biotech-installing-nemuco-in-biolab-on-the-international-space-station-9c9b1789ebcae427Pharma Surgeen2026-06-22T14:04:42.000ZOffworld Biotech: Installing NEMUCO In BioLab On The International Space Stationhttps://www.pharmaradar360.com/article/volontariato-28-06-un-concerto-per-sostenere-l-associazione-amici-della-clinica-9f7a522d273e777cPharma Surgeen2026-06-22T14:00:00.000Z#VOLONTARIATO [28.06] Un concerto per sostenere l'Associazione Amici della Clinica Neurochirurgicahttps://www.pharmaradar360.com/article/abbvie-seals-10-9b-deal-to-acquire-waltham-biotech-apogee-therapeutics-dae2fd37fe196ef8Pharma Surgeen2026-06-22T13:34:00.000ZAbbVie seals $10.9B deal to acquire Waltham biotech Apogee Therapeuticshttps://www.pharmaradar360.com/article/another-big-deal-another-sign-biotech-m-a-is-back-34baba61e0a6aa66Pharma Surgeen2026-06-22T13:22:37.000ZAnother big deal, another sign biotech M&A is backhttps://www.pharmaradar360.com/article/pride-month-clinical-research-as-activism-92d0a7b7716cb2dbPharma Surgeen2026-06-22T13:22:07.000ZPride Month: Clinical Research as Activismhttps://www.pharmaradar360.com/article/creative-medical-gets-fda-clearance-to-add-15-patients-in-olastrocel-trial-b330b35d801eff2dPharma Surgeen2026-06-22T13:15:00.000ZCreative Medical gets FDA clearance to add 15 patients in Olastrocel trialhttps://www.pharmaradar360.com/article/wissenschaftsjahr-2026-vier-forderprojekte-zur-wissenschaftskommunikation-in-hei-203cc78b0448f0acPharma Surgeen2026-06-22T13:13:41.000ZWissenschaftsjahr 2026: Vier Förderprojekte zur Wissenschaftskommunikation in Heidelberg und Mannheimhttps://www.pharmaradar360.com/article/genetische-diagnostik-leicht-erklart-mit-generation-genom-dein-code-deine-zukunf-9cd6add8b5a67f4aPharma Surgeen2026-06-22T13:13:12.000ZGenetische Diagnostik leicht erklärt mit „Generation Genom – Dein Code. Deine Zukunft.“https://www.pharmaradar360.com/article/von-a-wie-adhs-bis-z-wie-zukunftsangst-social-media-projekt-klart-zu-psychischer-635933a36252d2a7Pharma Surgeen2026-06-22T13:12:45.000ZVon A wie ADHS bis Z wie Zukunftsangst: Social-Media-Projekt klärt zu psychischer Gesundheit aufhttps://www.pharmaradar360.com/article/mit-rollenspielen-digitale-medizin-erleben-77d482feb31a8744Pharma Surgeen2026-06-22T13:12:19.000ZMit Rollenspielen digitale Medizin erlebenhttps://www.pharmaradar360.com/article/marius-pharmaceuticals-applauds-fda-s-proposed-testosterone-labeling-updates-as-23c49efe850ed947Pharma Surgeen2026-06-22T13:11:16.000ZMarius Pharmaceuticals Applauds FDA’s Proposed Testosterone Labeling Updates as a Turning Point for Men’s Healthhttps://www.pharmaradar360.com/article/healthscience4all-gemeinsam-gesundheit-machen-dced272207476e45Pharma Surgeen2026-06-22T13:11:00.000Z„HealthScience4All“: Gemeinsam Gesundheit machenhttps://www.pharmaradar360.com/article/education-alumnae-lead-cheers-in-canes-crew-2caf84bb2bf5e5cdPharma Surgeen2026-06-22T12:58:24.000ZEducation alumnae lead cheers in Canes Crewhttps://www.pharmaradar360.com/article/nuvectis-expands-pipeline-with-haisco-licensing-agreement-for-two-clinical-stage-1928ff791f91b125Pharma Surgeen2026-06-22T12:53:18.000ZNuvectis Expands Pipeline with Haisco Licensing Agreement for Two Clinical-Stage Drug Candidates (NVCT)https://www.pharmaradar360.com/article/poll-what-s-causing-the-spike-in-weight-loss-drug-mistakes-c1c377c03835652bPharma Surgeen2026-06-22T12:51:22.000ZPoll: What's causing the spike in weight-loss drug mistakes?https://www.pharmaradar360.com/article/cordis-project-the-natural-k-fe-and-cu-isotopic-response-to-pt-based-chemotherap-84fda8a5c778802aPharma Surgeen2026-06-22T12:40:16.000ZCORDIS project: The natural K, Fe, and Cu isotopic response to Pt-based chemotherapeutic drug resistance in ovarian cancerhttps://www.pharmaradar360.com/article/cordis-project-traffikgene-tx-targeted-peptide-carriers-for-rna-delivery-579538b01ad526c4Pharma Surgeen2026-06-22T12:39:21.000ZCORDIS project: TraffikGene-Tx: Targeted Peptide Carriers for RNA Deliveryhttps://www.pharmaradar360.com/article/cordis-project-miniaturized-plasma-emission-spectroscopy-based-breath-analysis-f-43236473e040bf14Pharma Surgeen2026-06-22T12:38:49.000ZCORDIS project: Miniaturized plasma emission spectroscopy-based breath analysis for unobtrusive at-home monitoring and prediction of COPD exacerbationshttps://www.pharmaradar360.com/article/cordis-project-cardiogenomics-meets-artificial-intelligence-a-step-forward-in-ar-38693778289e4f6ePharma Surgeen2026-06-22T12:38:18.000ZCORDIS project: Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatmenthttps://www.pharmaradar360.com/article/cordis-project-discovering-chronic-inflammation-biomarkers-that-define-key-stage-acea3a0923e81234Pharma Surgeen2026-06-22T12:35:44.000ZCORDIS project: Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategieshttps://www.pharmaradar360.com/article/dhsc-one-off-statistical-releases-a8a8056e5d3d3dabPharma Surgeen2026-06-22T12:34:11.000ZDHSC one-off statistical releaseshttps://www.pharmaradar360.com/article/cordis-project-training-the-next-generation-of-european-glioblastoma-translation-cbd94d9cd7616045Pharma Surgeen2026-06-22T12:34:04.000ZCORDIS project: Training the next-generation of European GLIOblastoma (translational) researchers, to RESOLVE precision targeting of the brain tumour microenvironmenthttps://www.pharmaradar360.com/article/estimated-impact-of-the-introduction-of-the-single-patient-record-b914a47d046c4557Pharma Surgeen2026-06-22T12:33:00.000ZEstimated impact of the introduction of the single patient recordhttps://www.pharmaradar360.com/article/achieve-life-fda-rejects-cytisinicline-filing-over-manufacturing-issues-d146bc5162910096Pharma Surgeen2026-06-22T12:30:00.000ZAchieve Life FDA rejects cytisinicline filing over manufacturing issueshttps://www.pharmaradar360.com/article/achieve-life-sciences-receives-complete-response-letter-from-fda-for-cytisinicli-3a51583b82abaff9Pharma Surgeen2026-06-22T12:30:00.000ZAchieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDAhttps://www.pharmaradar360.com/article/cordis-project-fcaecc-fellowship-programme-for-talented-researchers-in-cancer-f5bc47d7e53a4087Pharma Surgeen2026-06-22T12:27:12.000ZCORDIS project: FCAECC Fellowship programme for talented researchers in cancerhttps://www.pharmaradar360.com/article/cordis-project-next-generation-models-and-genetic-therapies-for-rare-neuromuscul-5376bfb2e40a86a9Pharma Surgeen2026-06-22T12:24:39.000ZCORDIS project: Next-generation models and genetic therapies for rare neuromuscular diseaseshttps://www.pharmaradar360.com/article/a-common-vitamin-could-help-fight-one-of-the-deadliest-brain-cancers-d23e540015c0efe6Pharma Surgeen2026-06-22T12:23:53.000ZA common vitamin could help fight one of the deadliest brain cancershttps://www.pharmaradar360.com/article/cough-cold-4e1edfaeb8bb579ePharma Surgeen2026-06-22T12:19:57.000ZCough & coldhttps://www.pharmaradar360.com/article/pain-management-dafd5b7f540add05Pharma Surgeen2026-06-22T12:19:57.000ZPain managementhttps://www.pharmaradar360.com/article/neurology-63b31e258c2d37e4Pharma Surgeen2026-06-22T12:19:57.000ZNeurologyhttps://www.pharmaradar360.com/article/cardiometabolic-aa6d4587a7321130Pharma Surgeen2026-06-22T12:19:57.000ZCardiometabolichttps://www.pharmaradar360.com/article/intim-health-5abe91496210d596Pharma Surgeen2026-06-22T12:19:57.000ZIntim healthhttps://www.pharmaradar360.com/article/gastroenterology-2257d60486d8dee0Pharma Surgeen2026-06-22T12:19:57.000ZGastroenterologyhttps://www.pharmaradar360.com/article/skin-care-ac1ea4a775c70d07Pharma Surgeen2026-06-22T12:19:57.000ZSkin carehttps://www.pharmaradar360.com/article/antibiotics-and-antiseptics-fad87fe3a4f2fedcPharma Surgeen2026-06-22T12:19:57.000ZAntibiotics and antisepticshttps://www.pharmaradar360.com/article/drugs-for-allergy-2fbb7bd128b0ddabPharma Surgeen2026-06-22T12:19:57.000ZDrugs for Allergyhttps://www.pharmaradar360.com/article/fb09a81eb57f8349Pharma Surgeen2026-06-22T12:19:57.000ZПрепарати від застуди та температуриhttps://www.pharmaradar360.com/article/63a817099fb88e7dPharma Surgeen2026-06-22T12:19:57.000ZПрепарати від болю та запаленняhttps://www.pharmaradar360.com/article/c99b583417679c1fPharma Surgeen2026-06-22T12:19:57.000ZНеврологічні препаратиhttps://www.pharmaradar360.com/article/215a3c23a9f76c2bPharma Surgeen2026-06-22T12:19:57.000ZКардіометаболічні препаратиhttps://www.pharmaradar360.com/article/180fc30068f63441Pharma Surgeen2026-06-22T12:19:57.000ZПрепарати для інтимного здоров'яhttps://www.pharmaradar360.com/article/bc702cacb4e44471Pharma Surgeen2026-06-22T12:19:57.000ZПрепарати для застосування у хірургіїhttps://www.pharmaradar360.com/article/6e6d58256e2049adPharma Surgeen2026-06-22T12:19:57.000ZГастроентерологічні препаратиhttps://www.pharmaradar360.com/article/8675dc58a4d32d6cPharma Surgeen2026-06-22T12:19:57.000ZДерматологічні препаратиhttps://www.pharmaradar360.com/article/ee3027f2271a1fa8Pharma Surgeen2026-06-22T12:19:57.000ZАнтибактеріальні препарати та антисептикиhttps://www.pharmaradar360.com/article/d94f61326c64b043Pharma Surgeen2026-06-22T12:19:57.000ZПрепарати при алергіїhttps://www.pharmaradar360.com/article/b3f3f978e8181105Pharma Surgeen2026-06-22T12:19:57.000ZПрепаратиhttps://www.pharmaradar360.com/article/biotech-deals-and-data-lit-a-fire-under-small-caps-46f1dade070cd2d9Pharma Surgeen2026-06-22T12:14:59.000ZBiotech Deals And Data Lit A Fire Under Small Capshttps://www.pharmaradar360.com/article/usz-erhalt-fordergelder-zur-erforschung-von-herzmuskelerkrankungen-9afa8ef28c2ec9daPharma Surgeen2026-06-22T12:14:46.000ZUSZ erhält Fördergelder zur Erforschung von Herzmuskelerkrankungenhttps://www.pharmaradar360.com/article/verrica-starts-phase-3-common-warts-trial-with-first-u-s-patient-26c4964861bb645aPharma Surgeen2026-06-22T12:05:00.000ZVerrica starts Phase 3 common-warts trial with first U.S. patienthttps://www.pharmaradar360.com/article/verrica-pharmaceuticals-announces-first-u-s-patient-dosed-5410e6a88c62adffPharma Surgeen2026-06-22T12:05:00.000ZVerrica Pharmaceuticals Announces First U.S. Patient Dosedhttps://www.pharmaradar360.com/article/insilico-s-ai-design-engine-bags-deal-with-korean-biotech-worth-possible-2-5b-c863d323fa4e5d1cPharma Surgeen2026-06-22T12:04:51.000ZInsilico’s AI design engine bags deal with Korean biotech worth possible $2.5B+https://www.pharmaradar360.com/article/designing-a-comprehensive-pipeline-for-crispr-safety-evaluation-6d2d6db9917b32bePharma Surgeen2026-06-22T12:00:00.000ZDesigning a Comprehensive Pipeline for CRISPR Safety Evaluationhttps://www.pharmaradar360.com/article/penumbra-system-red-68-reperfusion-catheter-a9f2ba17b2d6f39aPharma Surgeen2026-06-22T12:00:00.000ZPenumbra System RED 68 Reperfusion Catheterhttps://www.pharmaradar360.com/article/gyrus-acmi-classic-series-continuous-flow-resectoscope-150047aa06c5ed8aPharma Surgeen2026-06-22T12:00:00.000ZGyrus ACMI® Classic Series Continuous Flow Resectoscopehttps://www.pharmaradar360.com/article/abbvie-inks-10-9b-apogee-buyout-to-bag-eczema-prospect-172f6e257c3c7b29Pharma Surgeen2026-06-22T11:59:35.000ZAbbVie inks $10.9B Apogee buyout to bag eczema prospecthttps://www.pharmaradar360.com/article/andrew-mcewan-consultant-2b597fc76d49a217Pharma Surgeen2026-06-22T11:55:26.000ZAndrew McEwan - Consultanthttps://www.pharmaradar360.com/article/german-cancer-award-for-scientists-at-the-medical-faculty-heidelberg-a93243caaa070438Pharma Surgeen2026-06-22T11:49:38.000ZGerman Cancer Award for Scientists at the Medical Faculty Heidelberghttps://www.pharmaradar360.com/article/using-ai-to-close-the-post-market-design-loop-greenlight-guru-cb53504b2f3062c9Pharma Surgeen2026-06-22T11:40:35.000ZUsing AI to close the post-market design loop | Greenlight Guruhttps://www.pharmaradar360.com/article/from-fragmented-reporting-to-real-time-foresight-what-the-fda-s-aems-means-for-p-16c11c54d07fea9cPharma Surgeen2026-06-22T11:35:24.000ZFrom fragmented reporting to real-time foresight: What the FDA’s AEMS means for pharmacovigilancehttps://www.pharmaradar360.com/article/les-hopitaux-universitaires-de-strasbourg-remportent-le-challenge-des-foulees-ec-bf6b779392b0daabPharma Surgeen2026-06-22T11:35:15.000ZLes Hôpitaux Universitaires de Strasbourg remportent le Challenge des Foulées éco-solidaires pour la deuxième année consécutivehttps://www.pharmaradar360.com/article/les-hus-informent-et-accompagnent-les-patients-atteints-d-un-cancer-du-rein-a901820ea576070dPharma Surgeen2026-06-22T11:32:58.000ZLes HUS informent et accompagnent les patients atteints d’un cancer du reinhttps://www.pharmaradar360.com/article/insmed-extensive-phase-3-tpip-program-and-revenue-growth-in-q1-2026-strong-buy-7bcbafd5e98bac24Pharma Surgeen2026-06-22T11:30:38.000ZInsmed: Extensive Phase 3 TPIP Program And Revenue Growth In Q1 2026, Strong Buyhttps://www.pharmaradar360.com/article/covid-19-vaccination-spring-2026-campaign-resources-6896042b62ccb70dPharma Surgeen2026-06-22T11:25:40.000ZCOVID-19 vaccination: spring 2026 campaign resourceshttps://www.pharmaradar360.com/article/uk-public-health-rapid-support-team-uk-phrst-e9ece4baa927d83dPharma Surgeen2026-06-22T11:21:22.000ZUK Public Health Rapid Support Team (UK-PHRST)https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-vaccination-for-older-adults-b709407e14b34df9Pharma Surgeen2026-06-22T11:19:44.000ZRespiratory syncytial virus (RSV): vaccination for older adultshttps://www.pharmaradar360.com/article/exclusive-nsf-slashes-research-programs-to-support-new-tech-initiative-insiders-efd3e7eb7a1eff80Pharma Surgeen2026-06-22T11:15:00.000ZExclusive: NSF slashes research programs to support new tech initiative, insiders sayhttps://www.pharmaradar360.com/article/definium-lsd-therapy-helped-patients-with-major-depression-in-late-stage-trial-45fd7423ddb1ded7Pharma Surgeen2026-06-22T11:04:05.000ZDefinium LSD therapy helped patients with major depression in late-stage trialhttps://www.pharmaradar360.com/article/ukhsa-issues-red-heat-health-alerts-across-england-3ab1f8a5ec9bfc1dPharma Surgeen2026-06-22T11:01:07.000ZUKHSA issues red heat-health alerts across Englandhttps://www.pharmaradar360.com/article/moonlake-mltx-reveals-robust-phase-3-hs-data-and-targets-2026-bla-filing-6cc9bb09ebf5fc7fPharma Surgeen2026-06-22T11:00:32.000ZMoonLake (MLTX) reveals robust Phase 3 HS data and targets 2026 BLA filinghttps://www.pharmaradar360.com/article/definium-s-lsd-formula-produces-best-data-ever-seen-in-a-pivotal-depression-tria-2a84b96d45b601daPharma Surgeen2026-06-22T11:00:00.000ZDefinium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO sayshttps://www.pharmaradar360.com/article/definium-therapeutics-announces-positive-topline-results-from-phase-3-emerge-stu-706b36d30f9bd472Pharma Surgeen2026-06-22T11:00:00.000ZDefinium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorderhttps://www.pharmaradar360.com/article/a-dose-of-disruption-read-the-full-investigative-series-on-empower-711ba25d4b514405Pharma Surgeen2026-06-22T11:00:00.000ZA Dose of Disruption: Read the full investigative series on Empowerhttps://www.pharmaradar360.com/article/helmed-by-sanofi-vet-bionyra-emerges-with-165m-and-three-licensed-i-i-assets-292e6d9c5a3556bfPharma Surgeen2026-06-22T11:00:00.000ZHelmed by Sanofi vet, Bionyra emerges with $165M and three licensed I&I assetshttps://www.pharmaradar360.com/article/abbvie-to-acquire-apogee-therapeutics-deepening-immunology-portfolio-9b2e7536a11549b2Pharma Surgeen2026-06-22T11:00:00.000ZAbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfoliohttps://www.pharmaradar360.com/article/labcorp-announces-nationwide-availability-of-colosense-the-first-fda-approved-rn-068f3933db6b7cf8Pharma Surgeen2026-06-22T11:00:00.000ZLabcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Testhttps://www.pharmaradar360.com/article/ukhsa-update-on-the-hantavirus-cruise-ship-outbreak-3c646fc27267b263Pharma Surgeen2026-06-22T10:52:28.000ZUKHSA update on the hantavirus cruise ship outbreakhttps://www.pharmaradar360.com/article/renewal-of-vmps-2026-fcd9b4de0763265cPharma Surgeen2026-06-22T10:47:42.000ZRENEWAL OF VMPs 2026https://www.pharmaradar360.com/article/merck-s-tulisokibart-met-primary-and-key-secondary-endpoints-in-the-phase-3-atla-85af5c6c78bad7b8Pharma Surgeen2026-06-22T10:45:00.000ZMerck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)https://www.pharmaradar360.com/article/2026-e15cba17a9db6bebPharma Surgeen2026-06-22T10:42:43.000ZΑΝΑΝΕΩΣΕΙΣ ΚΤΗΝΙΑΤΡΙΚΩΝ ΠΡΟΪΟΝΤΩΝ 2026https://www.pharmaradar360.com/article/butterfly-that-barely-ages-could-help-unlock-longevity-secrets-595f4da50f791637Pharma Surgeen2026-06-22T10:30:08.000ZButterfly that barely ages could help unlock longevity secretshttps://www.pharmaradar360.com/article/innovo-therapeutics-scores-korean-phase-3-approval-for-scar-treatment-inv-001-65c52f19b3556c62Pharma Surgeen2026-06-22T10:13:36.000ZInnovo Therapeutics scores Korean phase 3 approval for scar treatment, INV-001https://www.pharmaradar360.com/article/tvtx-lgnd-stocks-in-spotlight-ahead-of-monday-s-fda-call-on-kidney-drug-filspari-fa6238499aaae213Pharma Surgeen2026-06-22T10:10:50.000ZTVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filsparihttps://www.pharmaradar360.com/article/icon-selects-microsoft-as-a-preferred-technology-partner-to-power-ai-enabled-cli-6d62bb6d794b913dPharma Surgeen2026-06-22T09:53:36.000ZICON Selects Microsoft as a Preferred Technology Partner to Power AI-Enabled Clinical Developmenthttps://www.pharmaradar360.com/article/heidelberg-among-the-top-three-universities-in-germany-c0776f33e63073ecPharma Surgeen2026-06-22T09:52:53.000ZHeidelberg Among the “Top Three” Universities in Germanyhttps://www.pharmaradar360.com/article/regulatory-round-up-22-june-2026-c0277841a453a61cPharma Surgeen2026-06-22T09:51:12.000ZRegulatory round-up: 22 June 2026https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-21-june-2026-6a0eead6dccb0816Pharma Surgeen2026-06-22T09:35:35.000ZWeekly all-cause mortality surveillance: week ending 21 June 2026https://www.pharmaradar360.com/article/world-refugee-day-showing-solidarity-with-refugees-in-south-africa-1c171c82a338e056Pharma Surgeen2026-06-22T09:14:19.000ZWorld Refugee Day: Showing solidarity with refugees in South Africahttps://www.pharmaradar360.com/article/what-the-first-joint-clinical-assessment-jca-report-tells-us-about-the-next-era-798d89dcf0acdf20Pharma Surgeen2026-06-22T09:11:56.000ZWhat the first Joint Clinical Assessment (JCA) report tells us about the next era of integrated evidence planning and access strategyhttps://www.pharmaradar360.com/article/la-adquisicion-de-rois-phoenix-marca-un-nuevo-hito-en-la-internacionalizacion-de-2fa01139f7d26eabPharma Surgeen2026-06-22T09:11:14.000ZLa adquisición de ROIS PHOENIX marca un nuevo hito en la internacionalización del negocio de fabricación a terceros de ROIShttps://www.pharmaradar360.com/article/women-living-with-ms-take-to-the-stage-in-powerful-showcase-7f459939722c5587Pharma Surgeen2026-06-22T09:03:17.000ZWomen living with MS take to the stage in powerful showcasehttps://www.pharmaradar360.com/article/does-drinking-juice-soda-during-childhood-increase-the-risk-of-high-blood-pressu-7ecd15e132fabe8ePharma Surgeen2026-06-22T09:00:00.000ZDoes drinking juice, soda during childhood increase the risk of high blood pressure?https://www.pharmaradar360.com/article/algae-microbots-take-aim-at-bladder-cancer-7c544810e644309fPharma Surgeen2026-06-22T08:51:26.000ZAlgae microbots take aim at bladder cancerhttps://www.pharmaradar360.com/article/ildong-pharmaceutical-group-to-attend-bio-usa-advance-global-partnering-for-glp-fdb4ba669c063225Pharma Surgeen2026-06-22T08:43:42.000ZIldong Pharmaceutical Group to attend BIO USA, advance global partnering for GLP-1 obesity drug candidateshttps://www.pharmaradar360.com/article/post-covid-syndrom-blutwasche-zeigt-in-studie-keinen-nutzen-fur-betroffene-8aec8256c4d917c0Pharma Surgeen2026-06-22T08:31:45.000ZPost-Covid-Syndrom: Blutwäsche zeigt in Studie keinen Nutzen für Betroffene